CN750

CAS No. 2098711-72-7

CN750( CN-750 | CN 750 )

Catalog No. M13320 CAS No. 2098711-72-7

CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CN750
  • Note
    Research use only, not for human use.
  • Brief Description
    CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.
  • Description
    CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM; shows Kd values of 33, 27, 24, 21, 20, 21, 18, 50, 20, 67, and 160 nM for BRD2 (BD1), BRD2 (BD1,2), BRD2 (BD2), BRD3 (BD1), BRD3 (BD1,2), BRD3 (BD2), BRD4 (BD1), BRD4 (BD2), BRDT (BD1), BRDT (BD1,2), and BRDT (BD2), respectively; CN750 is a pan BET family inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CN-750 | CN 750
  • Pathway
    Chromatin/Epigenetic
  • Target
    Bromodomain
  • Recptor
    Bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2098711-72-7
  • Formula Weight
    532.089
  • Molecular Formula
    C29H34ClN7O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN1C=C(C=CC1=O)C2=CC3=C(C=C2)N=C(N=C3NCC4=CC(=CC=C4)Cl)N5CCN(CC5)CCN(C)C
  • Chemical Name
    5-(4-((3-chlorobenzyl)amino)-2-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)quinazolin-6-yl)-1-methylpyridin-2(1H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yang SM, et al. Bioorg Med Chem Lett. 2018 Nov 15;28(21):3483-3488.
molnova catalog
related products
  • GW 841819X

    GW 841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomain.

  • Ischemin sodium

    A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

  • INCB054329

    INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.